VolitionRx (NYSE American: VNRX): Cancer Screening and Diagnostic Tests for Animals and Humans [Due Diligence Podcast]

My guest on the show today is Cameron Reynolds, President and CEO of VolitionRx Limited (NYSE AMERICAN: VNRX). Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. While the company has been primarily focused on human diagnostics and monitoring, it also has a subsidiary focused on animal diagnostics and monitoring. Even though Volition’s animal diagnostics and monitoring subsidiary is relatively new, the company recently announced a $28M deal with Heska Corporation for their low cost animal cancer screening and monitoring tests. I’ve known Volition for a long time, and want to chat with Cameron about: - Animal diagnostics and monitoring subsidiary - How this subsidiary fits with Volition’s strategy moving forward - Current status on their clinical trials for their blood tests - What Cameron thinks about the potential for their NETosis product With that, please enjoy my conversation with Cameron Reynolds, President and CEO of VolitionRx. For more information about VolitionRx, please visit: https://volition.com/ This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action. The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast. SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL’S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST. By accessing this podcast, the listener acknowledges that the entire contents and design of this podcast, are the property of SNN, or used by SNN with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this podcast may sav